Ashwani Verma
Stock Analyst at UBS
(4.16)
# 443
Out of 5,126 analysts
106
Total ratings
57.89%
Success rate
12.78%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $178 | $141.20 | +26.06% | 11 | Jan 23, 2026 | |
| INSM Insmed | Maintains: Buy | $223 → $215 | $149.86 | +43.47% | 1 | Jan 6, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $600 → $645 | $485.36 | +32.89% | 11 | Jan 6, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $163 → $248 | $182.55 | +35.85% | 6 | Jan 6, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $40 | $23.56 | +69.78% | 9 | Jan 6, 2026 | |
| CORT Corcept Therapeutics | Initiates: Neutral | $95 | $40.83 | +132.67% | 1 | Dec 16, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $54 → $48 | $17.10 | +180.70% | 4 | Dec 8, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $26 → $11 | $11.60 | -5.17% | 5 | Nov 26, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $163 → $188 | $165.50 | +13.60% | 7 | Nov 24, 2025 | |
| ALVO Alvotech | Maintains: Buy | $13 → $10 | $5.12 | +95.31% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $195 → $220 | $223.43 | -1.54% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $40 | $43.90 | -8.88% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $21.69 | -7.79% | 4 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $43 | $37.27 | +15.37% | 3 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $34.69 | -25.05% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $68 | $108.39 | -37.26% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $27.05 | -33.46% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $34.91 | +20.31% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $62.34 | -34.23% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $2.14 | -50.93% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $68.10 | +67.40% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $44.65 | -37.29% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $227.68 | -96.93% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $14.58 | -17.70% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.22 | +1,129.51% | 1 | Oct 11, 2022 |
Neurocrine Biosciences
Jan 23, 2026
Maintains: Buy
Price Target: $188 → $178
Current: $141.20
Upside: +26.06%
Insmed
Jan 6, 2026
Maintains: Buy
Price Target: $223 → $215
Current: $149.86
Upside: +43.47%
United Therapeutics
Jan 6, 2026
Maintains: Buy
Price Target: $600 → $645
Current: $485.36
Upside: +32.89%
Axsome Therapeutics
Jan 6, 2026
Maintains: Buy
Price Target: $163 → $248
Current: $182.55
Upside: +35.85%
ACADIA Pharmaceuticals
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $23.56
Upside: +69.78%
Corcept Therapeutics
Dec 16, 2025
Initiates: Neutral
Price Target: $95
Current: $40.83
Upside: +132.67%
Legend Biotech
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $17.10
Upside: +180.70%
Biohaven
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $11.60
Upside: -5.17%
Jazz Pharmaceuticals
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $165.50
Upside: +13.60%
Alvotech
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $5.12
Upside: +95.31%
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $223.43
Upside: -1.54%
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $43.90
Upside: -8.88%
Oct 28, 2025
Downgrades: Neutral
Price Target: $20
Current: $21.69
Upside: -7.79%
Oct 15, 2025
Maintains: Buy
Price Target: $50 → $43
Current: $37.27
Upside: +15.37%
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $34.69
Upside: -25.05%
Jul 30, 2025
Maintains: Neutral
Price Target: $62 → $68
Current: $108.39
Upside: -37.26%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $27.05
Upside: -33.46%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $34.91
Upside: +20.31%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $62.34
Upside: -34.23%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $2.14
Upside: -50.93%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $68.10
Upside: +67.40%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $44.65
Upside: -37.29%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $227.68
Upside: -96.93%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $14.58
Upside: -17.70%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.22
Upside: +1,129.51%